669002-19-1

Upstream product

• 123-75-1 pyrrolidine 
• 7371-94-0 2-[4-(bromomethyl)phenyl]acetonitrile 

Downstream Products

• 669002-73-7 2-methyl-2-(4-pyrrolidin-1-ylmethyl-phenyl)-propionitrile 
• 669002-75-9 2-(4-pyrrolidin-1-ylmethyl-phenyl)-propionitrile 
• 669002-79-3 ethyl (4-pyrrolidin-1-ylmethyl-phenyl)-acetate 
• 669002-20-4 2-[4-(pyrrolidin-1-yl-methyl)-phenyl]-ethylamine 

Relevant academic research and scientific papers

NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one of said amides. Said medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia, and diabetes as a result of the MCH receptor antagonism.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.